AH
Therapeutic Areas
Annexin Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANXV | Retinal Vein Occlusion (RVO) | Phase 2a |
Leadership Team at Annexin Pharmaceuticals
AF
Anna Frostegård
Chief Scientific Officer / Chief Medical Officer (CSO/CMO)
SA
Susanne Andersson
Chief Financial Officer (CFO)